Integra Lifesciences (NASDAQ:IART) Shares Up 0.2%

Share on StockTwits

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) shot up 0.2% during mid-day trading on Friday . The stock traded as high as $51.31 and last traded at $51.19. 6,381 shares were traded during trading, a decline of 98% from the average session volume of 385,958 shares. The stock had previously closed at $51.10.

Several research firms have recently issued reports on IART. ValuEngine lowered Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, April 18th. BidaskClub upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Tuesday, April 23rd. Finally, Oppenheimer dropped their price objective on Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $58.00.

The company has a debt-to-equity ratio of 0.95, a current ratio of 2.86 and a quick ratio of 1.86. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 1.46 and a beta of 0.97.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.04. The business had revenue of $359.69 million during the quarter, compared to the consensus estimate of $361.12 million. Integra Lifesciences had a return on equity of 15.60% and a net margin of 5.60%. Integra Lifesciences’s revenue for the quarter was up .7% on a year-over-year basis. During the same period in the prior year, the company earned $0.58 EPS. Equities analysts forecast that Integra Lifesciences Holdings Corp will post 2.7 EPS for the current year.

In other Integra Lifesciences news, Director Christian S. Schade sold 15,658 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $51.56, for a total value of $807,326.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.50% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Campbell Newman Asset Management Inc. raised its position in shares of Integra Lifesciences by 2.4% during the first quarter. Campbell Newman Asset Management Inc. now owns 9,278 shares of the life sciences company’s stock worth $517,000 after acquiring an additional 218 shares during the last quarter. Advisor Group Inc. raised its position in shares of Integra Lifesciences by 0.9% during the first quarter. Advisor Group Inc. now owns 30,842 shares of the life sciences company’s stock worth $1,719,000 after acquiring an additional 282 shares during the last quarter. Retirement Systems of Alabama raised its position in shares of Integra Lifesciences by 0.5% during the first quarter. Retirement Systems of Alabama now owns 92,086 shares of the life sciences company’s stock worth $5,131,000 after acquiring an additional 420 shares during the last quarter. American International Group Inc. raised its position in shares of Integra Lifesciences by 0.3% during the fourth quarter. American International Group Inc. now owns 144,447 shares of the life sciences company’s stock worth $6,515,000 after acquiring an additional 439 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its position in shares of Integra Lifesciences by 1.6% during the first quarter. Oregon Public Employees Retirement Fund now owns 28,250 shares of the life sciences company’s stock worth $1,574,000 after acquiring an additional 444 shares during the last quarter. Institutional investors own 82.27% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Zolmax and is the sole property of of Zolmax. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://zolmax.com/investing/integra-lifesciences-nasdaqiart-shares-up-0-2/3114392.html.

Integra Lifesciences Company Profile (NASDAQ:IART)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Stock Selection – What is cash flow?

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jefferies Financial Group Upgrades BRITVIC PLC/S  to Buy
Jefferies Financial Group Upgrades BRITVIC PLC/S to Buy
DubaiCoin Reaches Market Capitalization of $392,831.00
DubaiCoin Reaches Market Capitalization of $392,831.00
Aditus Trading 1.3% Higher  Over Last 7 Days
Aditus Trading 1.3% Higher Over Last 7 Days
Phore 24-Hour Trading Volume Reaches $53,599.00
Phore 24-Hour Trading Volume Reaches $53,599.00
ugChain  24 Hour Trading Volume Hits $267,788.00
ugChain 24 Hour Trading Volume Hits $267,788.00
Plus-Coin  Reaches Market Cap of $445,505.00
Plus-Coin Reaches Market Cap of $445,505.00


 
© 2006-2019 Zolmax.